IN2014MN02126A - - Google Patents

Info

Publication number
IN2014MN02126A
IN2014MN02126A IN2126MUN2014A IN2014MN02126A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A IN 2126MUN2014 A IN2126MUN2014 A IN 2126MUN2014A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A
Authority
IN
India
Prior art keywords
compounds
calcium
crac
channel
formula
Prior art date
Application number
Inventor
Nageswara Rao Irlapati
Zubair Abdul Wajid Shaikh
Vijay Pandurang Karche
Gokul Keruji Deshmukh
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN2126MUN2014 priority Critical patent/IN2014MN02126A/en
Publication of IN2014MN02126A publication Critical patent/IN2014MN02126A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof which modulate the activity of calcium release activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I)and pharmaceutical compositions containing such compounds thereof for treating managing and/or lessening the severity of diseases disorders syndromes or conditions associated with the modulation of calcium release activated calcium (CRAC) channel.
IN2126MUN2014 2012-05-02 2013-05-01 IN2014MN02126A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2126MUN2014 IN2014MN02126A (en) 2012-05-02 2013-05-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
IN2126MUN2014 IN2014MN02126A (en) 2012-05-02 2013-05-01
PCT/IB2013/053440 WO2013164769A1 (en) 2012-05-02 2013-05-01 Substituted pyridine compounds as crac modulators

Publications (1)

Publication Number Publication Date
IN2014MN02126A true IN2014MN02126A (en) 2015-09-11

Family

ID=48428565

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2126MUN2014 IN2014MN02126A (en) 2012-05-02 2013-05-01

Country Status (7)

Country Link
US (2) US9399638B2 (en)
EP (1) EP2844655A1 (en)
AU (1) AU2013255437A1 (en)
CA (1) CA2871270A1 (en)
IN (1) IN2014MN02126A (en)
WO (1) WO2013164769A1 (en)
ZA (1) ZA201407685B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
CA2914415A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
CN105367547B (en) * 2014-08-19 2019-04-23 北京桦冠生物技术有限公司 A kind of new synthesis process of oxazoline ketone antibiotic
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
CN107205971A (en) * 2014-11-18 2017-09-26 罗格斯，新泽西州立大学 New mitochondrial uncoupler for treating metabolic disease and cancer
US11311535B2 (en) * 2015-02-27 2022-04-26 Calcimedica, Inc. Pancreatitis treatment
WO2016187182A1 (en) 2015-05-18 2016-11-24 Beth Israel Deaconess Medical Center, Inc. Substance p, mast cell degranulation inhibitors, and peripheral neuropathy
LT3303330T (en) * 2015-06-03 2019-08-12 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
DK3331525T3 (en) 2015-08-07 2020-12-14 Calcimedica Inc Use of CRAC channel inhibitors to treat stroke and traumatic brain injury
CN109415363B (en) 2016-05-18 2021-07-20 罗格斯，新泽西州立大学 Novel mitochondrial uncoupling agents for the treatment of metabolic diseases and cancer
CN112088157B (en) * 2017-12-22 2023-12-26 拉文纳制药公司 Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors
TWI827583B (en) 2018-03-08 2024-01-01 美商英塞特公司 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-γ INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020053834A1 (en) 2018-09-14 2020-03-19 Rhizen Pharmaceuticals Sa Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
CN110407740A (en) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 A kind of synthetic method of the bromo- 2- ethylpyridine of 3-

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412257A (en) 2003-07-23 2006-10-03 Synta Pharmaceuticals Corp compounds for inflammation and immune related uses
KR20070057965A (en) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. Compounds for inflammation and immune-related uses
KR20070107022A (en) 2005-01-07 2007-11-06 신타 파마슈티칼스 코프. Compounds for inflammation and immune-related uses
WO2006081391A2 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
CA2595000C (en) 2005-01-25 2013-10-15 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
CA2639913A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
AU2007208239B2 (en) 2006-01-25 2013-04-18 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
JP5430944B2 (en) 2006-01-31 2014-03-05 シンタ ファーマシューティカルズ コーポレーション Pyridylphenyl compounds for inflammation and immune related applications
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US20120064121A1 (en) 2007-08-01 2012-03-15 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
PL2195311T3 (en) 2007-08-17 2011-08-31 Actelion Pharmaceuticals Ltd Pyridine derivatives as s1p1/edg1 receptor modulators
CN101854933A (en) 2007-09-10 2010-10-06 钙医学公司 Regulate the chemical compound of intracellular Ca2+
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5474941B2 (en) 2008-05-23 2014-04-16 グラクソ グループ リミテッド Nitrogen-containing tricyclic compounds and their use as antibacterial agents
DE102008031299B4 (en) 2008-07-02 2014-10-30 Acandis Gmbh & Co. Kg Filter for a blood vessel
MX2011002149A (en) 2008-08-27 2011-04-05 Calcimedica Inc Compounds that modulate intracellular calcium.
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US20100130522A1 (en) 2008-10-01 2010-05-27 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AR077971A1 (en) 2009-08-26 2011-10-05 Astrazeneca Ab UREA HETEROCICLICAL DERIVATIVES AND METHODS OF USE OF THE SAME
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
KR20130106410A (en) 2010-10-30 2013-09-27 루핀 리미티드 Oxazoline and isoxazoline derivatives as crac modulators
CA2834928C (en) 2011-05-03 2017-10-17 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2012325901A1 (en) 2011-10-19 2014-05-15 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
EP2844655A1 (en) 2015-03-11
US20160304506A1 (en) 2016-10-20
CA2871270A1 (en) 2013-11-07
WO2013164769A1 (en) 2013-11-07
ZA201407685B (en) 2015-11-25
AU2013255437A1 (en) 2014-11-13
US20150111900A1 (en) 2015-04-23
US9399638B2 (en) 2016-07-26

Similar Documents

Publication Publication Date Title
IN2014MN02126A (en)
IN2014MN02127A (en)
CO6430427A2 (en) BENZOFURANILO DERIVATIVES
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
GEP20166438B (en) Imidazopyrrolidinone compounds
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CR20110103A (en) HETEROARILOS SUBSTITUTED
IN2014CN04907A (en)
MX2015012478A (en) Methods and compositions for inhibition of bromodomain-containing proteins.
MD20140109A2 (en) Indole and indazole compounds that activate AMPK
IN2012DN00943A (en)
WO2012170931A3 (en) Compounds that modulate intracellular calcium
MX337711B (en) Compounds that modulate intracellular calcium.
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
EA026940B9 (en) Substituted chroman compounds as calcium sensing receptor modulators
WO2012170951A3 (en) Compounds that modulate intracellular calcium
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
UY36081A (en) METALOENZYME INHIBITING COMPOUNDS AS FUNGICIDES.
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
IN2015MN00421A (en)
MX357828B (en) Compositions comprising plasma growth factors for use in the treatment of neurodegenerative disorders.
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders